Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Tubby-like protein 1 (Tulp1) is a target of microRNA-134 and is down-regulated in experimental epilepsy.

Rodriguez AS, Engel T, Palfi A, Farrar GJ, Henshall DC, Jimenez-Mateos EM.

Int J Physiol Pathophysiol Pharmacol. 2017 Dec 25;9(6):178-187. eCollection 2017.

2.

Direct effects of phenformin on metabolism/bioenergetics and viability of SH-SY5Y neuroblastoma cells.

Geoghegan F, Chadderton N, Farrar GJ, Zisterer DM, Porter RK.

Oncol Lett. 2017 Nov;14(5):6298-6306. doi: 10.3892/ol.2017.6929. Epub 2017 Sep 14.

3.

Target 5000: Target Capture Sequencing for Inherited Retinal Degenerations.

Dockery A, Stephenson K, Keegan D, Wynne N, Silvestri G, Humphries P, Kenna PF, Carrigan M, Farrar GJ.

Genes (Basel). 2017 Nov 3;8(11). pii: E304. doi: 10.3390/genes8110304.

4.

A Novel Retinal Ganglion Cell Promoter for Utility in AAV Vectors.

Hanlon KS, Chadderton N, Palfi A, Blanco Fernandez A, Humphries P, Kenna PF, Millington-Ward S, Farrar GJ.

Front Neurosci. 2017 Sep 21;11:521. doi: 10.3389/fnins.2017.00521. eCollection 2017.

5.

Toward an elucidation of the molecular genetics of inherited retinal degenerations.

Farrar GJ, Carrigan M, Dockery A, Millington-Ward S, Palfi A, Chadderton N, Humphries M, Kiang AS, Kenna PF, Humphries P.

Hum Mol Genet. 2017 Aug 1;26(R1):R2-R11. doi: 10.1093/hmg/ddx185. Review.

6.

Panel-Based Population Next-Generation Sequencing for Inherited Retinal Degenerations.

Carrigan M, Duignan E, Malone CP, Stephenson K, Saad T, McDermott C, Green A, Keegan D, Humphries P, Kenna PF, Farrar GJ.

Sci Rep. 2016 Sep 14;6:33248. doi: 10.1038/srep33248.

7.

microRNA regulatory circuits in a mouse model of inherited retinal degeneration.

Palfi A, Hokamp K, Hauck SM, Vencken S, Millington-Ward S, Chadderton N, Carrigan M, Kortvely E, Greene CM, Kenna PF, Farrar GJ.

Sci Rep. 2016 Aug 16;6:31431. doi: 10.1038/srep31431.

8.

A novel homozygous truncating GNAT1 mutation implicated in retinal degeneration.

Carrigan M, Duignan E, Humphries P, Palfi A, Kenna PF, Farrar GJ.

Br J Ophthalmol. 2016 Apr;100(4):495-500. doi: 10.1136/bjophthalmol-2015-306939. Epub 2015 Oct 15.

9.

Gene expression changes during retinal development and rod specification.

Mansergh FC, Carrigan M, Hokamp K, Farrar GJ.

Mol Vis. 2015 Jan 20;21:61-87. eCollection 2015.

10.

Low-valent chemistry: an alternative approach to phosphorus-containing oligomers.

Kosnik SC, Farrar GJ, Norton EL, Cooper BF, Ellis BD, Macdonald CL.

Inorg Chem. 2014 Dec 15;53(24):13061-9. doi: 10.1021/ic502229w. Epub 2014 Dec 1.

PMID:
25435405
11.

Gene therapies for inherited retinal disorders.

Farrar GJ, Millington-Ward S, Chadderton N, Mansergh FC, Palfi A.

Vis Neurosci. 2014 Sep;31(4-5):289-307. doi: 10.1017/S0952523814000133. Epub 2014 Jun 20. Review.

PMID:
24949856
12.

Cell therapy using retinal progenitor cells shows therapeutic effect in a chemically-induced rotenone mouse model of Leber hereditary optic neuropathy.

Mansergh FC, Chadderton N, Kenna PF, Gobbo OL, Farrar GJ.

Eur J Hum Genet. 2014 Nov;22(11):1314-20. doi: 10.1038/ejhg.2014.26. Epub 2014 Feb 26.

13.

Effective delivery of large genes to the retina by dual AAV vectors.

Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S, Marrocco E, Rossi S, Giunti M, Palfi A, Farrar GJ, Polishchuk R, Auricchio A.

EMBO Mol Med. 2014 Feb;6(2):194-211. doi: 10.1002/emmm.201302948. Epub 2013 Dec 15.

14.

CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression.

Egan CM, Nyman U, Skotte J, Streubel G, Turner S, O'Connell DJ, Rraklli V, Dolan MJ, Chadderton N, Hansen K, Farrar GJ, Helin K, Holmberg J, Bracken AP.

Dev Cell. 2013 Aug 12;26(3):223-36. doi: 10.1016/j.devcel.2013.07.008.

15.

Mitochondrial disorders: aetiologies, models systems, and candidate therapies.

Farrar GJ, Chadderton N, Kenna PF, Millington-Ward S.

Trends Genet. 2013 Aug;29(8):488-97. doi: 10.1016/j.tig.2013.05.005. Epub 2013 Jun 4. Review.

PMID:
23756086
16.

Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy.

Chadderton N, Palfi A, Millington-Ward S, Gobbo O, Overlack N, Carrigan M, O'Reilly M, Campbell M, Ehrhardt C, Wolfrum U, Humphries P, Kenna PF, Farrar GJ.

Eur J Hum Genet. 2013 Jan;21(1):62-8. doi: 10.1038/ejhg.2012.112. Epub 2012 Jun 6.

17.

Efficacy of codelivery of dual AAV2/5 vectors in the murine retina and hippocampus.

Palfi A, Chadderton N, McKee AG, Blanco Fernandez A, Humphries P, Kenna PF, Farrar GJ.

Hum Gene Ther. 2012 Aug;23(8):847-58. doi: 10.1089/hum.2011.142. Epub 2012 Jul 20.

PMID:
22545762
18.

NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components.

Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC, O'Neill LA, Hollyfield JG, Humphries P.

Nat Med. 2012 May;18(5):791-8. doi: 10.1038/nm.2717.

19.

Protein misfolding and potential therapeutic treatments in inherited retinopathies.

Tam LC, Kiang AS, Campbell M, Keaney J, Farrar GJ, Humphries MM, Kenna PF, Humphries P.

Adv Exp Med Biol. 2012;723:567-72. doi: 10.1007/978-1-4614-0631-0_72. Review. No abstract available.

PMID:
22183379
20.

Gene-based therapies for dominantly inherited retinopathies.

Farrar GJ, Millington-Ward S, Chadderton N, Humphries P, Kenna PF.

Gene Ther. 2012 Feb;19(2):137-44. doi: 10.1038/gt.2011.172. Epub 2011 Nov 17. Review.

PMID:
22089493

Supplemental Content

Loading ...
Support Center